CRAI with 5-Fu and Octreotide (Oct) increased the ratio of TXB₂ to 6-k-PGF_1α.

No significant difference of TXB₂ was found among the 4 experimental groups. However, 6-k-PGF1α significantly increased in all 3 treatment groups. So the ratio of TXB2 to 6-k-PGF1α was significantly lower in the treatment groups as compared to the SAP group. The sham group had normal TXB2, 6-k-PGF1α, and ratio of TXB2 to 6-k-PGF1α. *: vs. SAP group, P<0.05; ☆: vs. SAP group, P<0.01; $: 5-FU group vs. Oct group, P<0.05; $$: 5-FU group vs. Oct group, P<0.01; #: 5-FU group or Oct group vs. 5-FU + Oct group, P<0.05; ##: 5-FU group or Oct group vs. 5-FU + Oct group, P<0.01.